We want to give full control to the pathologists, based on straightforward access to all the information required, to be able to make a diagnosis in an environment where they can understand the full complexity of the tumor in question.
It is no secret that healthcare is in a constant state of change. Orchard understands this, and has committed to embracing innovation as one of our core values. At Orchard, we commit to research, modernization, and leading-edge technology progression within the healthcare industry. We commit to creating, developing, and implementing new products and services with the goal of improving laboratory effectiveness, elevating patient care, and improving patient lives.
The ex vivo microscope could take as little as 30 seconds to look at each specimen and probably will end up being able to diagnose the majority with high accuracy.
Researchers at the Karolinska Institutet in Stockholm, Sweden, together with international collaborators, have completed a comprehensive international validation of artificial intelligence (AI) for diagnosing and grading prostate cancer. The study, published in Nature Medicine, shows that AI systems can identify and grade prostate cancer in tissue samples from different countries equally well as pathologists. The results suggest AI systems may be ready to be responsibly introduced as a complementary tool in prostate cancer care.
Data accessibility and interoperability will accelerate translational medicine and development of therapeutic breakthroughsJanuary 13, 2022, Philadelphia, PA and San Francisco, CA – Proscia, the leader in digital and computational pathology solutions, and Datavant, the leader in helping organizations securely connect health data, today announced a partnership that will provide life sciences companies with digitized pathology data to power the development of novel therapeutics and diagnostics. The partnership brings together Datavant’s patient privacy-preserving connectivity technology and the largest U.S. health data ecosystem with Proscia’s Concentriq® digital pathology platform.Pathology is undergoing a transformation to an image-based, data-driven paradigm across life sciences and diagnostics as labs shift from 150-year-old analog microscope-based practices. According to the CDC, 70% of medical decisions are based on laboratory data, much of which has remained siloed and disconnected from the flourishing healthcare data landscape. Pathology’s digital transformation, which has been accelerated by the COVID-19 pandemic and technology tailwinds, represents the emergence of one of the largest and richest new data mediums in healthcare. Proscia’s proprietary platform technology is powering diagnostic labs and life sciences organizations today, including 10 of the top 20 biopharma companies.Datavant’s technology, combined with Proscia’s platform and extensive library of pathology data, will help life sciences organizations link digital images, curated cancer datasets, and structured insights with other healthcare data in a privacy-preserving way to power next-generation R&D. This compliant linkage will support the development of novel biomarkers, accelerate clinical trials, and enable real-world evidence in pharma.“We’ve seen a wellspring of demand for structured pathology data, married with computational technologies, to power precision medicine R&D,” said David West, CEO of Proscia. “Our partnership with Datavant does two things: first, it brings new tools for protecting patient privacy, data security, and HIPAA compliance to our Concentriq base. Second, it helps link pathology data with partners in the Datavant ecosystem. Together, this will enable pharma and biotech companies to leverage this new digital medium, cultivating the advancement of new therapies and diagnostics. Ultimately, this data partnership represents the third prong of Proscia’s mission to accelerate medical breakthroughs with our platform, AI and data.”“Pathology data is one of the most difficult sources of data to transform into usable information,” noted President and Co-Founder of Datavant, Travis May. “Enabling compliant connectivity of digital pathology data to other research data bridges bench science and outcomes research, scaling and accelerating the development of highly tailored precision therapeutics for patients.”About ProsciaProscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and over 10 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.About DatavantDatavant’s mission is to connect the world’s health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building neutral, trusted and ubiquitous technology that protects the privacy of patients while supporting the exchange of identified and de-identified health data across tens of thousands of healthcare institutions.SOURCE: Proscia
Representation learning, also known as feature learning, is a new and rapidly expanding set of machine learning techniques with numerous promising applications in digital pathology. Graph-based models have emerged as powerful tools for solving complex image classification problems and accurately simulating biological systems, including cellular and tissue interactions.
Indica Labs, a leading provider of computational pathology software and services, is proud to announce that following ISO13485 certification, HALO AP® has received a CE Mark for use in primary diagnosis within the European Economic Area, Switzerland, and the UK.
Pathology News would like to pay tribute to one of the founders of our profession, Ronald S Weinstein who sadly passed away on December 3rd last year at the age of 83. Weinstein was known by some as the “father of telepathology,” and his medical career spanned nearly six decades.
Digital technologies are revolutionizing modern pathology, and digital pathology is expected to transform routine diagnosis as we know it. The advantages of digital pathology over traditional pathology methods are truly multitudinous, and even though the clinical adoption of digital pathology in health care settings has been somewhat slow, the increasing popularity of digital solutions has posed previously unacknowledged challenges.
Whole slide imaging (WSI) entails the use of systems to scan entire glass slides to generate digital tissue images. Since the emergence of whole slide scanning systems approximately two decades ago, there have been significant advances in WSI technologies.1 The potentials of WSI in pathology and disease diagnosis are tremendous. Indeed, WSI is set to transform modern pathology and the way diseases are diagnosed based on tissue biopsies.2 Instead of observing stained tissue slides under microscopes used in traditional pathology, digital whole slide images can be reviewed using computerized systems. In addition to remote slide reviewing, WSI also facilitates easy sharing of pathology images among collaborators across the globe. The adoption of WSI in pathology laboratories has reached unprecedented levels in recent years, and despite its many advantages, guidelines are required to confirm the performance and diagnostic accuracy of WSI systems before they are used for diagnostic purposes.
